Clinical guidance for HCPs evaluating patients with lung injury linked to use of e-cigarette products

CDC issued on Friday updated interim clinical guidance for health care providers caring for individuals with lung injury associated with use of e-cigarette, or vaping, products.

CDC issued on Friday updated interim clinical guidance for health care providers caring for individuals with lung injury associated with use of e-cigarette, or vaping, products. According to the agency, "This interim guidance offers clinicians a framework for their initial assessment, evaluation, management, and follow-up of people with symptoms of lung injury associated with use of e-cigarette, or vaping, products. It advises close follow-up of these patients, as some patients who initially had mild symptoms experienced a rapid worsening of symptoms within 48 hours." As of October 8, there were 1,299 cases of patients with lung injury associated with the use of e-cigarette or vaping products recorded in 49 states, the District of Columbia, and the U.S. Virgin Islands, with 26 deaths. CDC noted that it is continuing to refine its recommendations based on new data. At present, the cause or causes of the lung injuries has not been identified. "No one compound or ingredient has emerged as the cause of these illnesses to date and it may be that there is more than one cause of this outbreak. Available data suggest THC-containing products play a role in this outbreak," CDC said, adding that it recommends against use of e-cigarette or vaping products that contain THC. Additionally, it stressed that youth, young adults, and pregnant women should avoid all e-cigarette products.